2000
DOI: 10.1073/pnas.210253497
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A lterations in the ABL tyrosine kinase are characteristic genetic events in multiple forms of leukemia. In humans, leukemogenic forms of ABL arise from chromosomal translocations. In the resulting fusion proteins, residues encoded by the first exon of ABL are replaced by sequence from the BCR protein, resulting in 185-kDa and 210-kDa isoforms or, less frequently, from the TEL protein (1). In chronic myelogenous leukemia, p210 BCR͞ABL is found in 95% of all cases (2). These same hybrid proteins can transform c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
25
0

Year Published

2003
2003
2015
2015

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(26 citation statements)
references
References 47 publications
1
25
0
Order By: Relevance
“…Lack of knowledge of the mechanism of their inactivation prevents their application as potential therapeutic targets. Although an escort/phosphatase approach has been used to enhance the anti-transformation potential of SHP1 by increasing its affinity for bcr/abl (18), clinical application of this technique does not appear to be feasible. It is interesting that a Ser/Thr phosphatase PP2A whose activity is negatively regulated by bcr/abl-induced SET protein can also dephosphorylate bcr/abl by recruiting the tyrosine phosphatase SHP1 (19).…”
mentioning
confidence: 99%
“…Lack of knowledge of the mechanism of their inactivation prevents their application as potential therapeutic targets. Although an escort/phosphatase approach has been used to enhance the anti-transformation potential of SHP1 by increasing its affinity for bcr/abl (18), clinical application of this technique does not appear to be feasible. It is interesting that a Ser/Thr phosphatase PP2A whose activity is negatively regulated by bcr/abl-induced SET protein can also dephosphorylate bcr/abl by recruiting the tyrosine phosphatase SHP1 (19).…”
mentioning
confidence: 99%
“…The involvement of SHP-1 in the PP2A-induced negative regulation of BCR/ABL kinase activity and expression is also supported by the fact that SHP-1 associates with BCR/ABL and its tyrosine phosphatase activity counteracts BCR/ABL leukaemogenic potential (Liedtke et al, 1998;Lim et al, 2000). Accordingly, expression of SHP-1 is diminished in most of leukaemias and lymphomas, SHP-1 downregulation leads to abnormal cell growth and SHP-1 activity is suppressed by different oncogenic tyrosine kinases (e.g.…”
Section: Adverse Molecular Effects Of Bcr/abl and Pp2amentioning
confidence: 89%
“…In particular, SHP1 is associated with the BCR-ABL oncogenic tyrosine kinase. [39][40][41] SHP1 has also been shown to downregulate Src-family kinases such as Lck, Fyn, 42 and ZAP-70. 43,44 SHP1 also plays an important role in the negative regulation of the signaling pathway involving the JAK family kinases 19,45 and STATs.…”
Section: Discussionmentioning
confidence: 99%